Centessa Pharmaceuticals PLC
NASDAQ:CNTA

  • LAST PRICE
    16.0000
  • TODAY'S CHANGE (%)
    -1.5000 (-8.5714%)
  • Bid / Lots
    11.8800/ 2
  • Ask / Lots
    18.5000/ 2
  • Open / Previous Close
    17.7900 / 17.5000
  • Day Range
    15.9500
    17.7900
  • 52 Week Range
    5.5830
    18.7400
  • Volume
    730,650

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CNTA
Centessa Pharmaceuticals PLC
2.1B
-10.5x
---
GPCR
Structure Therapeutics Inc
2.0B
-15.5x
---
AKRO
Akero Therapeutics Inc
2.0B
-7.5x
---
GERN
Geron Corp
2.2B
-11.4x
---
CGON
CG Oncology Inc
2.2B
-27.7x
---
SLNO
Soleno Therapeutics Inc
2.2B
-15.6x
---
As of 2024-11-17

Company Information

Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.

Contact Information

Headquarters
3Rd Floor, 1 Ashley RoadALTRINCHAM, United Kingdom WA14 2DT
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Francesco de Rubertis
Chief Executive Officer, Director
Saurabh Saha
Chief Financial Officer
John Crowley
Chief People Officer
Karen Anderson
Executive Vice President and Chairman of Development
Antoine Yver

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.1B
Revenue (TTM)
$6.9M
Shares Outstanding
128.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.48
EPS
$-1.52
Book Value
$2.39
P/E Ratio
-10.5x
Price/Sales (TTM)
299.9
Price/Cash Flow (TTM)
---
Operating Margin
-2,358.87%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.